Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Traditional Chinese medicine injections plus routine western medicine for critically ill pandemic influenza A(H1N1)
ChiCTR-OCH-10000815Phase 4Recruiting
- Sponsor
- Institute of Basic Research in Clinical Medicine
- Start
- Jan 2010
- Modality
- Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of Reduning, andrographolide sulfonate, salvia miltiorrhiza, shenmai injection and shenfu injection in Influenza A virus subtype H1N1 infection (H1N1) (2 arms), sponsored by Institute of Basic Research in Clinical Medicine. Primary endpoints: Incidence of complications and Mortality. Started Jan 2010; status: recruiting.
02
Drugs
Reduningandrographolide sulfonatesalvia miltiorrhizashenmai injectionshenfu injection
03
Conditions
Influenza A virus subtype H1N1 infection (H1N1)
Beyond the preview
Go deeper on ChiCTR-OCH-10000815.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-OCH-10000815.